Hemostasis system correction in patients with cirrhosis

Authors

  • А. S. Tugushev Zaporizhzhia State Medical University,
  • D. I. Mikhantyev Local Сlinical Hospital on the Station Zaporizhzhia-2 of the Pridneprovsky Railway,
  • V. V. Neshta Local Сlinical Hospital on the Station Zaporizhzhia-2 of the Pridneprovsky Railway,
  • O. S. Cherkovska Zaporizhzhia State Medical University,
  • E. D. Ryazanova Zaporizhzhia State Medical University,

DOI:

https://doi.org/10.14739/2310-1210.2015.5.53772

Keywords:

Liver Cirrhosis, Hemostasis, Vikasolum, Anticoagulants

Abstract

Nature of violations of hemostasis system in cirrhosis is difficult, often unpredictable and concerns all its links. Thus both bleedings and thrombosis are possible. Disease decompensation is accompanied by deeper haemostatic imbalance towards thrombophilia. It is connected with that hepatocytes is the main place of synthesis vitamin K dependent pro- and anticoagulant proteins. Respectively, medical tactics should be directed on correction of pathogenetic mechanisms of haemostatic imbalance.

Aim. To estimate influence Vikasolum on pro- and anticoagulant link of hemostasis in patients with cirrhosis.

Methods and results. 30 patients with cirrhosis were under supervision. Patients received Vikasolum in dose 1.0 ml of 0.01 % solution intramuscularly 3 times a day within 3-4 days, with shift to oral route – on 1 tablet (0.015) twice a day up to 2 weeks. Estimation of procoagulant unit included determination of the number of platelets, prothrombin index, activated partial thromboplastin time, blood-coagulation factor F VIII, fibrinogen levels, «B» and D-dimer fibrinogen. Anticoagulant system was evaluated with activity of coagulation inhibitor of protein C.

It is shown that hemostasis condition is characterised by an imbalance towards hyper coagulation on the ground of normal or hyperactivated blood-coagulation factor F VIII in patients with cirrhosis. At appointment of vikasoli increase levels of a protrombin index and the protein C is noted.

Conclusion. Vikasolum intake promotes normalisation of a haemostatic imbalance, vitamin K dependent pro- and antikoagulyant factors synthesis.

References

Tugushev, A. S., Kremzer, A. A., Izbitskij, V. V., Nechepurenko, I. G., & Panchenko, L. V. (2011). Ocenka sistemy gemostaza pri cirroze pecheni [Assessment of system of a hemostasis at cirrhosis]. Zaporozhskij medicinskij zhurnal, 13(3), 74–75. [in Ukrainian].

Aggarwal, A., Puri, K., & Suthat, L. (2014). Deep vein thrombosis and pulmonary embolism in cirrhotic patients: Systematic review. World J Gastroenterol., 20(18), 5737–5745. doi: 10.3748/wjg.v20.i19.5737.

Arshad, F., Lisman, T., & Porte, R. J. (2013). Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. Liver International, 33(6), 820–827. doi: 10.1111/liv.12140.

Boyer, Th. D., & Habib, Sh. (2014). Portal vein thrombosis in patients with cirrhosis. Clinical Liver Disease, 3(6), 111–113.

Habib, M., Roberts, L. N., Patel, R. K., Wendon, J., Bernal, W., & Arya, R (2014). Evidence of rebalanced coagulation in acute liver injury and acute liver failure as measured by thrombin generation. Liver International, 34(5), 672–678. doi: 10.1111/liv.12369.

Intagliata, N. M., & Stephen, H. (2014). Management of disordered hemostasis and coagulation in patients with cirrhosis. Clinical Liver Disease, 3(6), 114–117. doi: 10.1002/cld.333.

Lisman, T., Kamphuisen, P. W., Northup, P.G., Porte, R. J. (2013). Established and new-generation antithrombotic drugs in patients with cirrhosis – Possibilities and caveats. J Hepatology, 59(2), 358–366. doi: 10.1016/j.jhep.2013.03.027.

Mallett, S. V., Chowdary, P., & Burroughs, A. K. (2013). Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver International, 33(7), 961–974.

Northup, P. G., & Caldwell, S. H. (2013). Coagulation in Liver Disease: A Guide for the Clinician. Clinical Gastroenterology and Hepatology, 11(9), 1064–1074. doi: 10.1016/j.cgh.2013.02.026.

Nusrat, S., Khan, M. S., Fazili, J., & Madhoun, M. F. (2014). Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol., 20(18), 5442–5460. doi: 10.3748/wjg.v20.i18.5442.

Rodriguez-Castro, K .I., Simioni, P., Burra, P., & Senzolo, M. (2012). Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver International, 32(10), 1465–1476. doi: 10.1111/j.1478-3231.2012.02839.x.

Tapper, E. B., Robson, S. C., & Malik, R. (2013). Coagulopathy in cirrhosis – The role of the platelet in hemostasis. J Hepatology, 59(4), 889–890. doi: 10.1016/j.jhep.2013.03.040.

Tripodi, A., Primignani, M., Lemma, L., Chantarangkul, V., & Mannucci, P. M. (2013) Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatology, 59(2), 265–270. doi: 10.1016/j.jhep.2013.03.036

How to Cite

1.
Tugushev АS, Mikhantyev DI, Neshta VV, Cherkovska OS, Ryazanova ED. Hemostasis system correction in patients with cirrhosis. Zaporozhye Medical Journal [Internet]. 2015Nov.20 [cited 2024Nov.25];17(5). Available from: http://zmj.zsmu.edu.ua/article/view/53772

Issue

Section

Original research